TRACON Pharmaceuticals to Present at the Oppenheimer 26th Annual Healthcare Conference

SAN DIEGO, Dec. 02, 2015 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present at the Oppenheimer 26th Annual Healthcare Conference at 2:10 pm EST on Wednesday, December 9, 2015, at the Westin Grand Central Hotel in New York, NY.

To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at A replay of the webcast will be available on the website for 60 days following the event.


TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The company’s clinical-stage pipeline includes two product candidates: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers and wet AMD through a collaboration with Santen Pharmaceutical Company Ltd., and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at

Company Contact: Investor Contact: Casey Logan Andrew McDonald Chief Business Officer LifeSci Advisors LLC (858) 550‐0780 ext. 236 646-597-6987

Source:TRACON Pharmaceuticals, Inc.